1999
Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial
Heier J, Cheetham J, DeGryse R, Dirks M, Caldwell D, Silverstone D, Rosenthal A. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial. American Journal Of Ophthalmology 1999, 127: 253-259. PMID: 10088733, DOI: 10.1016/s0002-9394(98)00413-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnterior ChamberAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodFemaleHumansKetorolac TromethamineLens Implantation, IntraocularMaleMiddle AgedOphthalmic SolutionsPain, PostoperativePhacoemulsificationSafetyTolmetinTreatment OutcomeTromethamineUveitis, AnteriorConceptsSevere anterior segment inflammationAnterior segment inflammationIntraocular lens implantationCataract surgeryVehicle solutionOphthalmic solutionLens implantationSubstantial anti-inflammatory activityVehicle-controlled clinical trialSafety of ketorolacAnterior chamber cellsParallel-group studyEye four timesUnilateral cataract surgerySevere ocular inflammationLack of efficacyAnti-inflammatory activityCiliary flushKetorolac groupTopical ketorolacAdverse eventsOcular inflammationOnly patientsVisual acuityIntraocular pressure
1991
Evaluation of Once-Daily Levobunolol 0.25% and Timolol 0.25% Therapy for Increased Intraocular Pressure
Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, Stoecker J, Kelley E, Lue J. Evaluation of Once-Daily Levobunolol 0.25% and Timolol 0.25% Therapy for Increased Intraocular Pressure. American Journal Of Ophthalmology 1991, 112: 56-60. PMID: 1882923, DOI: 10.1016/s0002-9394(14)76213-0.Peer-Reviewed Original ResearchConceptsOpen-angle glaucomaLevobunolol groupTimolol groupOcular hypertensionIntraocular pressureThree-month study periodIncreased Intraocular PressureOcular hypotensive efficacyOverall mean decreaseMean heart rateHypotensive efficacyBlood pressureClinical trialsHeart rateMean decreaseTreatment groupsThree monthsPatientsStudy periodHypertensionGlaucomaGroupLevobunololTimololTherapy